Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Up-and-coming researchers who are blazing a trail in their respective fields share what they are most excited about and where their research going in the next 5 years.
Nature Medicine asks leading researchers to name their top clinical trial for 2023, from cervical and prostate cancer screening to new drugs for Parkinson’s disease and Alzheimer’s disease.
This year saw breakthroughs in several fields, spurred by research in basic science and technology. Here is our selection of critical developments that moved medicine forward in 2022.
Checkpoint-blockade immunotherapy has transformed cancer therapeutics but still benefits only a subset of patients. The development of more-robust biomarkers of response could change that.
Identification and characterization of variants in HTR2C in people with severe obesity, reveals a role for serotonin 2C receptor in regulation of appetite, weight and behavior.
A variant of the IL7 gene predicts the toxicity of checkpoint inhibitors in patients with cancer, via a mechanism shared with autoimmune diseases — which could inform biomarker and treatment strategies in both of these contexts.
A genome-wide association study in large cohorts of patients with different types of cancer treated with immune checkpoint inhibitors identifies genetic variants associated with immune-related adverse events.
Genetic analyses in a cohort of patients with melanoma receiving immunotherapy reveal that variants in IL7 are associated with immune-related adverse events and highlight the role of B cells in mediating toxicity.
Gender-affirming care for transgender and gender diverse people should be inclusive, community led and evidence informed to support mental health and wellbeing.